Expert Review of Endocrinology & Metabolism · 2025 · 12 citations · 26 references
MedicineEndocrinologyBone MetabolismReproductive EndocrinologyWomen's HealthBone EndocrinologyBone HealthBone Metabolism DisordersOsteoporosisBlood Sample CollectionBone Mineral DensityBone Mineral Density ScreeningEarly ScreeningEstrogen Effects On Bone DensityOsteoporosis In WomenOxidative BiomarkersOxidative Stress Biomarkers
OBJECTIVES: Raised asprosin may be related to the development of postmenopausal osteoporosis. This study aimed to determine the role of asprosin in oxidative stress in postmenopausal osteoporosis and its relation with estrogen, osteoprotegerin (OPG), and bone mineral density (BMD). METHODS: A case-control study included 80 women, aged 42-65, presenting at Shalamar Hospital, Lahore, Pakistan. Informed consent was taken, and single blinding was done. Demographic details and a bone mineral density scan were done. Three ml of venous blood sample was taken to measure asprosin, glutathione (GSH), osteoprotegerin, and estrogen levels. RESULTS: < 0.05). The cutoff value of serum asprosin for screening postmenopausal osteoporosis by area under the curve was > 27.4 ng/ml with a sensitivity of 75% and a 1-specificity of 14%. CONCLUSION: Higher serum asprosin and oxidative stress biomarkers are related to decreased bone mineral density in postmenopausal women. Asprosin may be used as a potential biomarker for early screening of postmenopausal osteoporosis. Small sample size and observational study design were the key limitations of this study.
26
Asprosin, a Fasting-Induced Glucogenic Protein Hormone
Chase Romere, Clemens Duerrschmid, Juan C. Bournat et al. · Cell · 2016 · 574 citations · Full text
Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Carmen Streicher, A. Heyny, Olena Andrukhova et al. · Scientific Reports · 2017 · 249 citations · Full text